tradingkey.logo
tradingkey.logo
Search

Metagenomi Inc

MGX
Add to Watchlist
1.310USD
-0.040-2.96%
Close 05/15, 16:00ETQuotes delayed by 15 min
49.32MMarket Cap
LossP/E TTM

Metagenomi Inc

1.310
-0.040-2.96%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.96%

5 Days

-7.09%

1 Month

-9.03%

6 Months

-24.71%

Year to Date

-19.14%

1 Year

-21.08%

TradingKey Stock Score of Metagenomi Inc

Currency: USD Updated: 2026-05-15

Key Insights

Metagenomi Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 100 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Metagenomi Inc's Score

Industry at a Glance

Industry Ranking
100 / 382
Overall Ranking
222 / 4482
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Metagenomi Inc Highlights

StrengthsRisks
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.21M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 25.21M.
Overvalued
The company’s latest PE is -0.57, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.82M shares, decreasing 42.09% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 628.40K shares of this stock.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
8.333
Target Price
+503.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Metagenomi Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Metagenomi Inc Info

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Ticker SymbolMGX
CompanyMetagenomi Inc
CEOIrish (Jian)
Websitehttps://metagenomi.co/
KeyAI